Male hypogonadism in overweight and obesity

Abstract

Obesity-related gonadal dysfunction in males has been defined recently as male obesity secondary hypogonadism (MOSH). Affected individuals present with signs and symptoms related to the sex hormone imbalance but also with a burden of metabolic risk factors and occasionally compromised fertility. In pathophysiological terms, excess body fat is associated with leptin and insulin resistance. Accelerated synthesis of leptin and hyperinsulinemia downregulate the expression of kisspeptin receptors and, consequently, the action of kisspeptin. This critical neuropeptide is known to control gonadotropin secretion. In obese males, enhanced activity of the aromatase enzyme is associated with an increase in the conversion of circulating testosterone to estrogen, further promoting a state of hypogonadism. In addition, high fat and low fiber intake alter the intestinal microbiome and the dysfunction of the gut-brain axis. Weight loss appears to be the key to readjusting the function of the hypothalamus-pituitary-gonadal axis. It can be achieved with lifestyle measures in combination with weight loss medications or bariatric surgery. The degree of weight loss appears to resolve the symptoms related to hypogonadism and improve fertility chances. However, the role of hormone replacement is also important, as testosterone replacement has been shown to reduce fat mass and increase the amount of lean body mass while also contributing to weight loss and the regulation of body mass index and waist circumference. This narrative review analyzes the evidence on developing obesity-related endocrinopathies and the available management options. Further research is required to estimate the cut-off of body mass index associated with a higher risk for hypogonadism.

Keywords

Obesity-related endocrinopathies / metabolic obesity secondary hypogonadism / weight loss / bariatric surgery

References

[1] WorldObesity.org. One billion people globally estimated to be living with obesity by 2030. Available from: https://www.worldobesity.org/resources/resource-library/world-obesity-atlas-2022 [Last accessed on 12 Jun 2023]

[2] Safaei M,Driss M,Shapi'i A.A systematic literature review on obesity: understanding the causes & consequences of obesity and reviewing various machine learning approaches used to predict obesity.Comput Biol Med2021;136:104754

[3] Bischoff SC,Cederholm T.Towards a multidisciplinary approach to understand and manage obesity and related diseases.Clin Nutr2017;36:917-38

[4] Stanford FC,Kyle TK.Media and its influence on obesity.Curr Obes Rep2018;7:186-92 PMCID:PMC5959781

[5] Vecchié A,Carbone F.Obesity phenotypes and their paradoxical association with cardiovascular diseases.Eur J Intern Med2018;48:6-17

[6] Schulze MB.Metabolic health in normal-weight and obese individuals.Diabetologia2019;62:558-66

[7] Leisegang K,Agarwal A.Obesity and metabolic syndrome associated with systemic inflammation and the impact on the male reproductive system.Am J Reprod Immunol2019;82:e13178

[8] Corona G,Huhtaniemi I.European academy of andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: endorsing organization: European society of endocrinology.Andrology2020;8:970-87

[9] Gurayah AA,Masterson JM,Ramasamy R.U-shaped association between prevalence of secondary hypogonadism and body mass index: a retrospective analysis of men with testosterone deficiency.Int J Impot Res2023;35:374-7 PMCID:PMC9346090

[10] Rastrelli G,Ahern T.EMAS Study GroupDevelopment of and recovery from secondary hypogonadism in aging men: prospective results from the EMAS.J Clin Endocrinol Metab2015;100:3172-82

[11] Tajar A,O'Neill TW.EMAS GroupCharacteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study.J Clin Endocrinol Metab2010;95:1810-8

[12] Aggerholm AS,Toft G,Bonde JP.Is overweight a risk factor for reduced semen quality and altered serum sex hormone profile?.Fertil Steril2008;90:619-26

[13] Calderón B,Calañas A.Effects of bariatric surgery on male obesity-associated secondary hypogonadism: comparison of laparoscopic gastric bypass with restrictive procedures.Obes Surg2014;24:1686-92

[14] Calderón B,Vega-Piñero B.Prevalence of male secondary hypogonadism in moderate to severe obesity and its relationship with insulin resistance and excess body weight.Andrology2016;4:62-7

[15] Dhindsa S,Dhindsa G.The effects of hypogonadism on body composition and bone mineral density in type 2 diabetic patients.Diabetes Care2007;30:1860-1

[16] Escobar-Morreale HF,Luque-Ramírez M.Prevalence of 'obesity-associated gonadal dysfunction' in severely obese men and women and its resolution after bariatric surgery: a systematic review and meta-analysis.Hum Reprod Update2017;23:390-408

[17] Hofstra J,van Wageningen B.High prevalence of hypogonadotropic hypogonadism in men referred for obesity treatment.Neth J Med2008;66:103-109.

[18] Rigon FA,Hohl A.Effects of bariatric surgery in male obesity-associated hypogonadism.Obes Surg2019;29:2115-25

[19] Wu FC,Beynon JM.EMAS GroupIdentification of late-onset hypogonadism in middle-aged and elderly men.N Engl J Med2010;363:123-35

[20] Dhindsa S,Jenkins T.High prevalence of subnormal testosterone in obese adolescent males: reversal with bariatric surgery.Eur J Endocrinol2022;186:319-27

[21] van Hulsteijn LT,Casanueva F.Prevalence of endocrine disorders in obese patients: systematic review and meta-analysis.Eur J Endocrinol2020;182:11-21

[22] Bonomi M,Krausz C.Italian Network on Central HypogonadismItalian Network on Central Hypogonadism (NICe group)Characteristics of a nationwide cohort of patients presenting with isolated hypogonadotropic hypogonadism (IHH).Eur J Endocrinol2018;178:23-32

[23] Kapoor D,Clark S,Jones TH.Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity.Diabetes Care2007;30:911-7

[24] Liu CC,Lee YC.The prevalence of and risk factors for androgen deficiency in aging Taiwanese men.J Sex Med2009;6:936-46

[25] Mulligan T,Zuraw QC,McWhirter C.Prevalence of hypogonadism in males aged at least 45 years: the HIM study.Int J Clin Pract2006;60:762-9 PMCID:PMC1569444

[26] Fernandez CJ,Pappachan JM.Male obesity-related secondary hypogonadism - pathophysiology, clinical implications and management.Eur Endocrinol2019;15:83-90 PMCID:PMC6785957

[27] Genchi VA,Lauriola C.Adipose tissue dysfunction and obesity-related male hypogonadism.Int J Mol Sci2022;23:8194 PMCID:PMC9330735

[28] Carrageta DF,Alves MG.Obesity and male hypogonadism: tales of a vicious cycle.Obes Rev2019;20:1148-58

[29] Kawai T,Scalia R.Adipose tissue inflammation and metabolic dysfunction in obesity.Am J Physiol Cell Physiol2021;320:C375-91 PMCID:PMC8294624

[30] Yazıcı D.Insulin resistance, obesity and lipotoxicity.Adv Exp Med Biol2017;960:277-304.

[31] Grossmann M,Cheung AS.Late-onset hypogonadism: metabolic impact.Andrology2020;8:1519-29

[32] Harris RB.Direct and indirect effects of leptin on adipocyte metabolism.Biochim Biophys Acta2014;1842:414-23 PMCID:PMC3838442

[33] Parent AS,Gérard A,Bourguignon JP.Leptin effects on pulsatile gonadotropin releasing hormone secretion from the adult rat hypothalamus and interaction with cocaine and amphetamine regulated transcript peptide and neuropeptide Y.Regul Pept2000;92:17-24

[34] Quennell JH,Tups A.Leptin indirectly regulates gonadotropin-releasing hormone neuronal function.Endocrinology2009;150:2805-12 PMCID:PMC2732287

[35] Marcouiller F,Ganouna-Cohen G.Metabolic responses to intermittent hypoxia are regulated by sex and estradiol in mice.Am J Physiol Endocrinol Metab2021;320:E316-25 PMCID:PMC8260369

[36] Ishikawa T,Ishimura T,Fujisawa M.Expression of leptin and leptin receptor in the testis of fertile and infertile patients.Andrologia2007;39:22-7

[37] Giovambattista A,Nessralla CC.Modulatory effects of leptin on leydig cell function of normal and hyperleptinemic rats.Neuroendocrinology2003;78:270-9

[38] Khodamoradi K,Seetharam D.The role of leptin and low testosterone in obesity.Int J Impot Res2022;34:704-13

[39] Rubinow KB.Estrogens and body weight regulation in men.Adv Exp Med Biol2017;1043:285-313. PMCID:PMC5835337

[40] Aftab SA, Kumar S, Barber TM. The role of obesity and type 2 diabetes mellitus in the development of male obesity-associated secondary hypogonadism.Clin Endocrinol2013;78:330-7

[41] Cohen PG.Aromatase, adiposity, aging and disease. the hypogonadal-metabolic-atherogenic-disease and aging connection.Med Hypotheses2001;56:702-8

[42] Grossmann M.Testosterone and glucose metabolism in men: current concepts and controversies.J Endocrinol2014;220:R37-55

[43] Grossmann M.Hypogonadism and male obesity: focus on unresolved questions.Clin Endocrinol2018;89:11-21

[44] Childs GV,MacNicol MC.The importance of leptin to reproduction.Endocrinology2021;162 PMCID:PMC7749705

[45] Jamieson BB.Kisspeptin neuron electrophysiology: Intrinsic properties, hormonal modulation, and regulation of homeostatic circuits.Front Neuroendocrinol2022;66:101006

[46] Ghaderpour S,Heydari H.The relation between obesity, kisspeptin, leptin, and male fertility.Horm Mol Biol Clin Investig2021;43:235-47

[47] Anawalt BD.Aging and androgens: physiology and clinical implications.Rev Endocr Metab Disord2022;23:1123-37

[48] Barber TM,Kaltsas G.Mechanisms of central hypogonadism.Int J Mol Sci2021;22:8217 PMCID:PMC8348115

[49] Ahmad R.Obesity: a doorway to a molecular path leading to infertility.Cureus2022;14:e30770 PMCID:PMC9612950

[50] Chang B,Gao H.Leptin and inflammatory factors play a synergistic role in the regulation of reproduction in male mice through hypothalamic kisspeptin-mediated energy balance.Reprod Biol Endocrinol2021;19:12 PMCID:PMC7816398

[51] Braga PC,Ribeiro JC.Late-onset hypogonadism and lifestyle-related metabolic disorders.Andrology2020;8:1530-8

[52] Xie Q,Zhang C.The role of kisspeptin in the control of the hypothalamic-pituitary-gonadal axis and reproduction.Front Endocrinol2022;13:925206 PMCID:PMC9273750

[53] Tremellen K.Gut endotoxin leading to a decline in gonadal function (GELDING) - a novel theory for the development of late onset hypogonadism in obese men.Basic Clin Androl2016;26:7 PMCID:PMC4918028

[54] Santacroce L,Ballini A.Testicular immunity and its connection with the microbiota. physiological and clinical implications in the light of personalized medicine.J Pers Med2022;12:1335 PMCID:PMC9409709

[55] Pearce KL,Tremellen KP.Obesity related metabolic endotoxemia is associated with oxidative stress and impaired sperm DNA integrity.Basic Clin Androl2019;29:6 PMCID:PMC6513521

[56] Barber TM,Mastorakos G.Dietary influences on the microbiota-gut-brain axis.Int J Mol Sci2021;22:3502 PMCID:PMC8038019

[57] Dimopoulou C,Corona G.The complex association between metabolic syndrome and male hypogonadism.Metabolism2018;86:61-8

[58] Rastrelli G,Sforza A,Corona G.Metabolic Syndrome in Male Hypogonadism. In: Popovic V, Korbonits M, editors. Metabolic syndrome consequent to endocrine disorders. S. Karger AG; 2018. pp. 131-55.

[59] Mangiola S,McCoy P.Androgen deprivation therapy promotes an obesity-like microenvironment in periprostatic fat.Endocr Connect2019;8:547-58 PMCID:PMC6499921

[60] Boban M.Cardiovascular diseases and androgen deprivation therapy.Acta Clin Croat2019;58:60-3 PMCID:PMC8693560

[61] Bhasin S,Singh R.The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action.J Gerontol A Biol Sci Med Sci2003;58:M1103-10

[62] Herbst KL.Testosterone action on skeletal muscle.Curr Opin Clin Nutr Metab Care2004;7:271-7

[63] Singh R,Taylor WE,Bhasin S.Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway.Endocrinology2003;144:5081-8

[64] Kelly DM.Testosterone and obesity.Obes Rev2015;16:581-606

[65] Xu XF,Björntorp P.Testosterone increases lipolysis and the number of beta-adrenoceptors in male rat adipocytes.Endocrinology1991;128:379-82

[66] Pergola G. The adipose tissue metabolism: role of testosterone and dehydroepiandrosterone.Int J Obes Relat Metab Disord2000;24 Suppl 2:S59-63

[67] Hernández-Morante JJ,Luján JA,Garaulet M.Role of DHEA-S on body fat distribution: gender- and depot-specific stimulation of adipose tissue lipolysis.Steroids2008;73:209-15

[68] Olivecrona G.Role of lipoprotein lipase in lipid metabolism.Curr Opin Lipidol2016;27:233-41

[69] M.; Mårin, P.; Björntorp, P. Effect of testosterone on abdominal adipose tissue in men.Int J Obes1991;15:791-795.

[70] Mårin P,Andersson B.Assimilation of triglycerides in subcutaneous and intraabdominal adipose tissues in vivo in men: effects of testosterone.J Clin Endocrinol Metab1996;81:1018-22

[71] Kim S,Park JH.A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease.BMC Gastroenterol2012;12:69 PMCID:PMC3406998

[72] Stellato RK,Hamdy O,McKinlay JB.Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study.Diabetes Care2000;23:490-4

[73] Lugari S,Lonardo A.Metabolic primary liver cancer in adults: risk factors and pathogenic mechanisms.Metab Target Organ Damage2023;3:5

[74] Hawksworth DJ.nonalcoholic fatty liver disease, male sexual dysfunction, and infertility: common links, common problems.Sex Med Rev2020;8:274-85

[75] Yim JY,Kim D.Serum testosterone and non-alcoholic fatty liver disease in men and women in the US.Liver Int2018;38:2051-9

[76] Jaruvongvanich V,Riangwiwat T.Testosterone, sex hormone-binding globulin and nonalcoholic fatty liver disease: a systematic review and meta-analysis.Annals of Hepatology2017;16:382-94

[77] Lazo M,Nasir K.Association between endogenous sex hormones and liver fat in a multiethnic study of atherosclerosis.Clin Gastroenterol Hepatol2015;13:1686-93.e2 PMCID:PMC4500744

[78] Charlton M,Chalasani N.Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease.Hepatology2008;47:484-92 PMCID:PMC2906146

[79] Koehler E,Sanderson S.Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients.Liver Int2012;32:279-86

[80] Wang WB,Xie LF.Evaluation of basal serum adrenocorticotropic hormone and cortisol levels and their relationship with nonalcoholic fatty liver disease in male patients with idiopathic hypogonadotropic hypogonadism.Chin Med J2016;129:1147-53 PMCID:PMC4878158

[81] Lonardo A,Carulli N.'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis.J Hepatol2006;44:1196-207

[82] Bobjer J,Tsatsanis C,Giwercman A.Negative association between testosterone concentration and inflammatory markers in young men: a nested cross-sectional study.PLoS One2013;8:e61466 PMCID:PMC3630214

[83] Ebrahimi F,Straumann S.IL-1 antagonism in men with metabolic syndrome and low testosterone: a randomized clinical trial.J Clin Endocrinol Metab2018;103:3466-76

[84] Willis SA,Malaikah S.The role of hepatic lipid composition in obesity-related metabolic disease.Liver Int2021;41:2819-35

[85] Mody A,Kanwal F.Relevance of low testosterone to non-alcoholic fatty liver disease.Cardiovasc Endocrinol2015;4:83-9 PMCID:PMC4577238

[86] Seo NK,Haam JH.Prediction of prevalent but not incident non-alcoholic fatty liver disease by levels of serum testosterone.J Gastroenterol Hepatol2015;30:1211-6

[87] Barbonetti A,Cotugno M.Low testosterone and non-alcoholic fatty liver disease: evidence for their independent association in men with chronic spinal cord injury.J Spinal Cord Med2016;39:443-9 PMCID:PMC5102293

[88] Gild P,Krasnova A.Liver disease in men undergoing androgen deprivation therapy for prostate cancer.J Urol2018;200:573-81

[89] Albhaisi S,Baker J.LPCN 1144 resolves NAFLD in hypogonadal males.Hepatol Commun2020;4:1430-40 PMCID:PMC7527694

[90] Sakr HF,Eid EA.Possible mechanisms underlying fatty liver in a rat model of male hypogonadism: a protective role for testosterone.Steroids2018;135:21-30

[91] Schleich F.Effects of androgen substitution on lipid profile in the adult and aging hypogonadal male.Eur J Endocrinol2004;151:415-24

[92] Peters JM,Ram PA.Peroxisome proliferator-activated receptor alpha required for gene induction by dehydroepiandrosterone-3 beta-sulfate.Mol Pharmacol1996;50:67-74.

[93] Lonardo A,Lugari S.NAFLD in some common endocrine diseases: prevalence, pathophysiology, and principles of diagnosis and management.Int J Mol Sci2019;20:2841 PMCID:PMC6600657

[94] Loria P,Bertolotti M.Endocrine and liver interaction: the role of endocrine pathways in NASH.Nat Rev Gastroenterol Hepatol2009;6:236-47

[95] Harada N,Hanada K.Hypogonadism alters cecal and fecal microbiota in male mice.Gut Microbes2016;7:533-9 PMCID:PMC5153613

[96] Liebe R,Bock HH.Diagnosis and management of secondary causes of steatohepatitis.J Hepatol2021;74:1455-71

[97] Huh JH,Kim SU.Obesity is more closely related with hepatic steatosis and fibrosis measured by transient elastography than metabolic health status.Metabolism2017;66:23-31

[98] Lonardo A,Lugari S.Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity.Ann Hepatol2020;19:359-66

[99] Man S,Yu C.Association between metabolically healthy obesity and non-alcoholic fatty liver disease.Hepatol Int2022;16:1412-23

[100] Kouvari M,Skoumas J.ATTICA study InvestigatorsThe presence of NAFLD influences the transition of metabolically healthy to metabolically unhealthy obesity and the ten-year cardiovascular disease risk: a population-based cohort study.Metabolism2022;128:154893

[101] Kouvari M,Yannakoulia M.ATTICA study investigatorsTransition from metabolically benign to metabolically unhealthy obesity and 10-year cardiovascular disease incidence: the ATTICA cohort study.Metabolism2019;93:18-24

[102] Nead KT.Androgens and depression: a review and update.Curr Opin Endocrinol Diabetes Obes2019;26:175-9

[103] Vermeer A, Riečanský I, Eisenegger C. Competition, testosterone, and adult neurobehavioral plasticity.Prog Brain Res2016;229:213-238

[104] Yang L,Tong Y.Neuroprotection by dihydrotestosterone in LPS-induced neuroinflammation.Neurobiol Dis2020;140:104814

[105] Wang H,Sun Z.Microglia in depression: an overview of microglia in the pathogenesis and treatment of depression.J Neuroinflammation2022;19:132 PMCID:PMC9168645

[106] Sallam MY,El-Mas MM.Androgenic modulation of arterial baroreceptor dysfunction and neuroinflammation in endotoxic male rats.Brain Res2021;1756:147330

[107] Westley CJ,Irwig MS.High rates of depression and depressive symptoms among men referred for borderline testosterone Levels.J Sex Med2015;12:1753-60

[108] Karolczak K,Soltysik B.Relationships between plasma concentrations of testosterone and dihydrotestosterone and geriatric depression scale scores in men and women aged 60-65 years-a multivariate approach with the use of quade’s test.Int J Environ Res Public Health2022;19:12507 PMCID:PMC9566053

[109] Makhlouf AA,Seftel AD.Hypogonadism is associated with overt depression symptoms in men with erectile dysfunction.Int J Impot Res2008;20:157-61

[110] Younossi ZM,Golabi P.The impact of fatigue on mortality of patients with non-alcoholic fatty liver disease: data from national health and nutrition examination survey 2005-2010 and 2017-2018.Liver Int2022;42:2646-61

[111] Surdea-Blaga T.Depression and anxiety in nonalcoholic steatohepatitis: is there any association?.Rom J Intern Med2011;49:273-280.

[112] Colognesi M,De Martin S.Depression and cognitive impairment-extrahepatic manifestations of NAFLD and NASH.Biomedicines2020;8:229 PMCID:PMC7400092

[113] Lonardo A.Perspectives of nonalcoholic fatty liver disease research: a personal point of view.Exploration of Medicine2020;1:85-107

[114] Balzano T,Borreda I.Histological features of cerebellar neuropathology in patients with alcoholic and nonalcoholic steatohepatitis.J Neuropathol Exp Neurol2018;77:837-45

[115] Giménez-Garzó C,Urios A.The PHES battery does not detect all cirrhotic patients with early neurological deficits, which are different in different patients.PLoS One2017;12:e0171211 PMCID:PMC5287470

[116] Youssef NA,Binks M.Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease.Liver Int2013;33:1062-70

[117] Nocito A,Jochum W.Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis.Gastroenterology2007;133:608-18

[118] Osawa Y,Seki E.L-tryptophan-mediated enhancement of susceptibility to nonalcoholic fatty liver disease is dependent on the mammalian target of rapamycin.J Biol Chem2011;286:34800-8 PMCID:PMC3186417

[119] Abosi O,Schmitz S.Cardiometabolic effects of psychotropic medications.Horm Mol Biol Clin Investig2018;36 PMCID:PMC6818518

[120] Skiba R,Syryło T,Rymarz A.Advanced chronic kidney disease is a strong predictor of hypogonadism and is associated with decreased lean tissue mass.Int J Nephrol Renovasc Dis2020;13:319-27 PMCID:PMC7653405

[121] Holley JL.The hypothalamic-pituitary axis in men and women with chronic kidney disease.Adv Chronic Kidney Dis2004;11:337-341

[122] Dunkel L,Laine J.Circulating luteinizing hormone receptor inhibitor(s) in boys with chronic renal failure.Kidney Int1997;51:777-84

[123] Schmidt A,Hörl WH.Sexual hormone abnormalities in male patients with renal failure.Nephrol Dial Transplant2002;17:368-71

[124] Peces R,López-Novoa JM.Hyperprolactinemia in chronic renal failure: impaired responsiveness to stimulation and suppression. normalization after transplantation.Nephron1981;28:11-6

[125] Romejko K,Sadownik H.Testosterone deficiency as one of the major endocrine disorders in chronic kidney disease.Nutrients2022;14:3438 PMCID:PMC9415930

[126] Fukui M,Ose H,Yoshikawa T.Role of endogenous androgen against insulin resistance and athero- sclerosis in men with type 2 diabetes.Curr Diabetes Rev2007;3:25-31

[127] Pivonello R,Riccio E.Metabolic Disorders and male hypogonadotropic hypogonadism.Front Endocrinol2019;10:345 PMCID:PMC6669361

[128] Fang T,Wang Y.Diagnostic value of visceral adiposity index in chronic kidney disease: a meta-analysis.Acta Diabetol2023;60:739-48

[129] Zheng X,Shen S.Association between visceral adiposity index and chronic kidney disease: evidence from the china health and retirement longitudinal study.Nutr Metab Cardiovasc Dis2022;32:1437-44

[130] Cobo G,Amparo FC.Visceral adipose tissue and leptin hyperproduction are associated with hypogonadism in men with chronic kidney disease.J Ren Nutr2017;27:243-8

[131] Navaneethan SD,Remer EM.CRIC Study InvestigatorsAdiposity, physical function, and their associations with insulin resistance, inflammation, and adipokines in CKD.Am J Kidney Dis2021;77:44-55 PMCID:PMC7752817

[132] Lonardo A,Targher G.Nonalcoholic fatty liver disease and chronic kidney disease: epidemiology, pathogenesis, and clinical and research implications.Int J Mol Sci2022;23:13320 PMCID:PMC9654863

[133] Kim SD.Obstructive sleep apnea and testosterone deficiency.World J Mens Health2019;37:12-8 PMCID:PMC6305865

[134] Wittert G.The relationship between sleep disorders and testosterone.Curr Opin Endocrinol Diabetes Obes2014;21:239-43

[135] Luboshitzky R,Shen-Orr Z,Lavie P.Disruption of the nocturnal testosterone rhythm by sleep fragmentation in normal men.J Clin Endocrinol Metab2001;86:1134-9

[136] Luboshitzky R,Hefetz A.Decreased pituitary-gonadal secretion in men with obstructive sleep apnea.J Clin Endocrinol Metab2002;87:3394-8

[137] Chen Y,Zhao S.Association of night-time sleep and day napping with the prevalence of MOSH in young obese men.Andrology2021;9:1872-8

[138] De Lorenzo A,Moriconi E.MOSH syndrome (Male Obesity Secondary Hypogonadism): clinical assessment and possible therapeutic approaches.Nutrients2018;10:474 PMCID:PMC5946259

[139] Corona G,Monami M.Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis.Eur J Endocrinol2013;168:829-43

[140] Pellitero S,Alastrue A.Hypogonadotropic hypogonadism in morbidly obese males is reversed after bariatric surgery.Obes Surg2012;22:1835-42

[141] Miñambres I,Urgell E.Obesity surgery improves hypogonadism and sexual function in men without effects in sperm quality.J Clin Med2022;11:5126 PMCID:PMC9457146

[142] Furini C,Simoni M,Santi D.Ketogenic state improves testosterone serum levels-results from a systematic review and meta-analysis.Endocrine2023;79:273-82

[143] Al Qurashi AA,Lund S.The effects of bariatric surgery on male and female fertility: A systematic review and meta-analysis.Ann Med Surg2022;80:103881 PMCID:PMC9422049

[144] Wei Y,Qian W.Effect of bariatric surgery on semen parameters: a systematic review and meta-analysis.Med Sci Monit Basic Res2018;24:188-97 PMCID:PMC6243830

[145] Samavat J,Lotti F.Massive weight loss obtained by bariatric surgery affects semen quality in morbid male obesity: a preliminary prospective double-armed study.Obes Surg2018;28:69-76

[146] Wood GJA,Paluello DV.Bariatric surgery impact on reproductive hormones, semen analysis, and sperm DNA fragmentation in men with severe obesity: prospective study.Obes Surg2020;30:4840-51

[147] Colleluori G,Turin CG.Aromatase inhibitors plus weight loss improves the hormonal profile of obese hypogonadal men without causing major side effects.Front Endocrinol2020;11:277 PMCID:PMC7243137

[148] Shah T,Shin D.Efficacy of anastrozole in the treatment of hypogonadal, subfertile men with body mass index ≥ 25 kg/m².Transl Androl Urol2021;10:1222-8 PMCID:PMC8039603

[149] Lapauw B.Management of endocrine disease: rationale and current evidence for testosterone therapy in the management of obesity and its complications.Eur J Endocrinol2020;183:R167-83

[150] Caliber M.Important lessons about testosterone therapy- weight loss vs. testosterone therapy for symptom resolution, classical vs. functional hypogonadism, and shortterm vs. lifelong testosterone therapy.Aging Male2020;23:585-91

[151] Isidori AM,Calogero A.Adult- and late-onset male hypogonadism: the clinical practice guidelines of the Italian society of andrology and sexual medicine (SIAMS) and the Italian society of endocrinology (SIE).J Endocrinol Invest2022;45:2385-403 PMCID:PMC9415259

[152] Lonardo A,Targher G.Precision medicine approaches in metabolic disorders and target organ damage: where are we now, and where are we going?.MTOD2021;